Clinical Trial Detail

NCT ID NCT03742349
Title Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals

triple-receptor negative breast cancer


Canakinumab + LAG525 + Spartalizumab

LAG525 + MCS110 + Spartalizumab

Capmatinib + LAG525 + Spartalizumab

LAG525 + PBF-509 + Spartalizumab

Age Groups: adult senior

No variant requirements are available.